Navigation Links
Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results

AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the fourth quarter and year ended December 31, 2011.  Financial and operating highlights include the following:


  • Consolidated fourth quarter 2011 revenue was $47.9 million, a 16 percent increase over the fourth quarter of 2010; full-year 2011 revenue was $184.3 million, a 30 percent increase over 2010
  • Fourth quarter 2011 assay sales of $16.4 million grew 77 percent over the fourth quarter of 2010; full-year 2011 assay revenue was $48.7 million, a 51 percent increase over 2010 and included a contribution from EraGen Biosciences, Inc. that exceeded the high end of our expectations for 2011 revenue
  • Fourth quarter 2011 shipments of 307 multiplexing analyzers that included 114 MAGPIX® systems, resulted in cumulative life-to-date multiplexing analyzer shipments of 8,678
  • Consolidated gross profit margin of 67.9 percent for the fourth quarter of 2011, which included the negative impact on gross profit margin resulting from the recording of EraGen inventory acquired at fair value on the date of acquisition  
  • Operating income for the fourth quarter of 2011 was $3.9 million. Included in this amount is approximately $1.1 million in incremental expense resulting from recording the EraGen inventory acquired at fair value on the date of acquisition and approximately $0.5 million in acquisition/integration costs associated with EraGen. Excluding the revaluing of EraGen inventory and acquisition costs, non-GAAP operating income for the fourth quarter of 2011 was $5.5 million, a $0.4 million increase over the fourth quarter of 2010
  • GAAP net income for the fourth quarter of 2011 was $3.4 million, or $0.08 per diluted share. GAAP net income for the full-year 2011 was $14.5 million or $0.34 per diluted share, compared to full-year 2010 net income of $5.2 million or $0.12 per diluted share. Excluding the aforementioned fair value adjustment to EraGen inventory and integration expenses, non-GAAP net income for the fourth quarter and 2011 was $4.8 million and $19.3 million or $0.11 and $0.45 per diluted share, respectively

  • "Luminex's strong fourth quarter performance completed a year that was full of achievements," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "In 2011, Luminex delivered 30 percent total revenue growth, driven by our higher margin revenue categories; assays, consumables, and royalties. The assay group, led by our Cystic Fibrosis and Respiratory Viral Panel franchises, and a healthy contribution from our acquisition of EraGen Biosciences, generated 51 percent growth over 2010. As forecasted, consumable revenue in the second half of the year decelerated from an exceptionally strong first half, yet for the full year, consumable revenue grew 38 percent over 2010. Finally, we recognized 30 percent growth in royalty revenue in 2011, which reflects the continuing strong commitment to and investment in our proprietary technology by our key partners." 

    "During 2011 we achieved several significant milestones, including the launch of our novel xTAG® Gastrointestinal Pathogen Panel in Europe, FDA clearance of our xTAG RVP FAST assay, and the acquisition of EraGen Biosciences. We believe these new products will begin to make a meaningful contribution in 2012," added Balthrop. "We are excited about the prospects for growth and remain focused on delivering innovative, high performance solutions to our customers. We believe our focus on the customer will continue to drive long-term value for our shareholders," Balthrop concluded. REVENUE SUMMARY(in thousands, except percentages)Three Months EndedDecember 31,Variance20112010($)(%)(unaudited)System sales

    $  10,449$  10,304$
    451%Consumable sales

    10,09311,954(1,861)-16%Royalty revenue

    7,0876,0441,04317%Assay revenue

    16,4019,2427,15977%All other revenue

    3,8393,6461935%$  47,869$  41,190$  6,67916%Twelve Months EndedDecember 31,Variance20112010($)(%)(unaudited)System sales

    $  35,901$  32,984$  2,9179%Consumable sales

    55,45740,10415,35338%Royalty revenue

    29,20522,4146,79130%Assay revenue

    48,67032,20416,46651%All other revenue

    15,10613,8511,2559%$184,339$141,557$42,78230%LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(in thousands, except percentages)Three Months EndedDecember 31,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships

    $  29,715$  30,550$
    (835)-3%Assays and related products

    18,15410,6407,51471%Total Revenue

    47,86941,1906,67916%Operating income (loss)Technology and strategic partnerships

    4,2395,872(1,633)-28%Assays and related products

    (307)(789)48261%Total Operating income

    3,9325,083(1,151)-23%Twelve Months EndedDecember 31,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships

    $127,779$105,586$22,19321%Assays and related products

    56,56035,97120,58957%Total Revenue

    184,339141,55742,78230%Operating income (loss)Technology and strategic partnerships

    29,89515,97713,91887%Assays and related products

    (6,052)(4,726)(1,326)-28%Total Operating income

    23,84311,25112,592112%FINANCIAL OUTLOOK AND GUIDANCE The Company intends to provide annual revenue guidance, to be updated, as appropriate, at each quarterly reporting period. Guidance for fiscal 2012 is as follows:

  • The Company expects fiscal 2012 revenue to be between $205 million to $215 million, or an increase of between 11 to 17 percent over reported 2011 revenue.

  • CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the fourth quarter ended December 31, 2011, on Monday, February 6, 2012, at 5:00 p.m. Eastern time/ 4:00 p.m. Central time.  The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base; expanded distribution for our MAGPIX system; the development progress of our NeoPlex4 assay product; market acceptance of our RVP FAST and GPP assay products; integration of EraGen Biosciences, Inc.; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2012 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets, into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2012 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.Contacts:

    Harriss T. Currie

    Matthew ScaloVice President, Finance and Chief Financial Officer

    Sr. Director of Investor Relations512-219-8020 LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)December 31,December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    89,487Restricted cash

    1,0061,002Short-term investments

    42,57428,404Accounts receivable, net

    23,01620,936Inventories, net

    24,57924,932Deferred income taxes

    5,9914,225Prepaids and other

    3,5292,732Total current assets

    158,977171,718Property and equipment, net

    25,19222,084Intangible assets, net

    29,43712,944Deferred income taxes

    12,8176,363Long-term investments



    7,3104,430Total assets

    265,810LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    7,621Accrued liabilities

    11,0477,444Deferred revenue

    4,0573,866Current portion of long term debt

    999849Total current liabilities

    22,04419,780Long-term debt

    2,5733,351Deferred revenue


    3,8313,511Total liabilities

    31,79230,945Stockholders' equity:Common stock

    4141Additional paid-in capital

    297,104295,422Accumulated other comprehensive gain

    9841,150Accumulated deficit

    (47,274)(61,748)Total stockholders' equity

    250,855234,865Total liabilities and stockholders' equity

    265,810LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Revenue

    $ 47,869$ 41,190$
    84,339$ 141,557Cost of revenue

    15,35012,61158,84945,180Gross profit

    32,51928,579125,49096,377Operating expenses:Research and development

    9,8827,84133,39426,843Selling, general and administrative

    17,61015,08164,87856,119Amortization of acquired intangible assets

    1,0955743,3752,164Total operating expenses

    28,58723,496101,64785,126Income from operations

    3,9325,08323,84311,251Interest expense from long-term debt

    (73)(85)(308)(419)Other income, net

    107119394519Income before income taxes

    3,9665,11723,92911,351Income taxes

    (524)(1,918)(9,455)(6,120)Net income

    $  3,442$  3,199$
    5,231Net income per share, basic

    .13Shares used in computing net income per share, basic

    41,15341,19941,26241,030Net income per share, diluted

    .12Shares used in computing net income per share, diluted

    42,37642,67142,53742,438The Company has reclassified certain amounts previously classified as a component of selling, general and administrative expenses to research and development expenses to conform to the current period presentation. This reclassification was $1.1 million and $3.4 million for the three and twelve months ended December 31, 2010, and was not material to the Company's consolidated financial statements. LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Cash flows from operating activities:Net income

    $   3,442$   3,199$
    4,474$   5,231Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization

    3,4622,40411,8878,898Stock-based compensation

    3,1162,51111,4179,436Deferred income tax benefit (expense)

    (2,058)2,101(592)5,591Excess income tax benefit from employee stock-based awards


    354(140)232709Changes in operating assets and liabilities:Accounts receivable, net

    (2,303)(1,867)(899)2,199Inventories, net

    1,410(746)4,783(5,811)Other assets

    (575)(178)(1,279)(332)Accounts payable

    (786)646(2,680)(1,776)Accrued liabilities

    5,1315319,324(506)Deferred revenue

    (283)(654)(763)536Net cash provided by operating activities

    9,6419,09738,29024,175Cash flows from investing activities:Purchases of available-for-sale securities

    (13,474)(3,008)(47,743)(29,673)Maturities of available-for-sale securities

    8,0377,50033,75323,693Purchase of property and equipment

    (2,434)(2,540)(9,554)(11,102)Business acquisition consideration, net of cash acquired

    -24(33,914)(5,012)Increase in restricted cash

    ---(1,000)Purchase of cost method investment

    -(5)(2,000)(2,081)Acquired technology rights

    (1,331)(625)(1,857)(1,825)Net cash (used in) provided by investing activities

    (9,202)1,346(61,315)(27,000)Cash flows from financing activities:Payments on debt

    --(885)(895)Proceeds from issuance of common stock

    1097263,5432,173Payments for stock repurchases

    (8,600)-(18,340)-Excess income tax benefit from employee stock-based awards

    1,269(1,290)7,614-Net cash (used in) provided by financing activities

    (7,222)(564)(8,068)1,278Effect of foreign currency exchange rate on cash

    (16)379(112)191Change in cash and cash equivalents

    (6,799)10,258(31,205)(1,356)Cash and cash equivalents, beginning of period

    65,08179,22989,48790,843Cash and cash equivalents, end of period

    $ 58,282$ 89,487$
    58,282$ 89,487LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Income from operations

    ,251Fair value markup of inventory

    1,091-3,321-Acquisition/Integration costs

    500-2,119-Adjusted income from operations

    ,251LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands, except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2011201020112010(unaudited)(unaudited)Net income

    $ 3,442$ 3,199$  14,474$ 5,231Fair value markup of inventory

    1,091-3,321-Acquisition/Integration costs

    500-2,119-Income tax effect

    (222)(638)Adjusted net income

    $ 4,811$ 3,199$  19,276$ 5,231Adjusted net income per share, basic

    $   0.12$   0.08$
    .47$   0.13Shares used in computing net income per share, basic

    41,15341,19941,26241,030Adjusted net income per share, diluted

    $   0.11$   0.07$
    .45$   0.12Shares used in computing net income per share, diluted


    SOURCE Luminex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
    2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
    3. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
    4. Luminex Corporation to Present at UBS Global Life Sciences Conference
    5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
    6. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
    7. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
    8. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
    9. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
    10. Luminex Corporation Reports Third Quarter 2010 Results
    11. Luminex Corporation to Present at Stephens Fall Investment Conference
    Post Your Comments:
    (Date:10/9/2015)... Calif. , Oct. 9, 2015 AcelRx Pharmaceuticals, ... will be made at the annual European Society of Emergency ... to October 14 th , 2015 at the Lingotto Congress ... EuSEM is the largest meeting of emergency medicine practitioners in ... countries represented. Data from the previously announced phase ...
    (Date:10/9/2015)... 2015 Ansun BioPharma announced a presentation at ... ) regarding the compassionate use of DAS181 under an ... who was co-infected with influenza and parainfluenza (Abstract # ... O 2 requirement was reduced and the patient,s ... go off the respirator on day 5. Between day ...
    (Date:10/9/2015)... -- Der " JCA-Mauvernay Award   2015 ... und Dr.   Junko Takita    --> Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr. ...    ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, wird am ...
    Breaking Medicine Technology:
    ... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
    ... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
    Cached Medicine Technology:
    (Date:10/10/2015)... , ... October 10, 2015 , ... "I have to walk with crutches for the ... 6.1 million Americans who live this way. Anything that would give me more independence and ... without having to use my hands." , He developed the STRAP IN to enable an ...
    (Date:10/10/2015)... ... 10, 2015 , ... Story Chaser is a one-of-a-kind app that ... classics and inspiring stories and as words drop down and users tap the corresponding ... aesthetic and can be interacted with, making it a more engaging game. Users can ...
    (Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern ... to be recognized by The National Law Journal for inclusion in their second ... firms across the United States who obtained the largest awards for their personal ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation ... Graduate Medical Education J. Michael Finley, DO, as the recipient of the 2015 ... his impact on graduate medical education opportunities for osteopathic residents, and his dedication ...
    (Date:10/9/2015)... , ... October 09, 2015 , ... With the FCPX ... pop grades to footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. This pack comes with 60 vibrant CUBE LUT files. ...
    Breaking Medicine News(10 mins):
    ... mind,s reward centers are less enthused, brain scans find , ... you see your paycheck may have a lot to do ... by researchers at the University of Bonn in Germany. , ... male volunteers divided into pairs. Each pair, in adjoining brain ...
    ... with a devastating brain injury that has wiped out ... to understand other peoples feelings and intentions, according to ... the Baycrest Centre for Aging and the Brain, and ... The study, published in the Nov. 23, 2007 issue ...
    ... midday sleepiness, experts say, , , THURSDAY, Nov. 22 (HealthDay ... the Thanksgiving feast aren,t rare, and experts say a ... holiday. , It may have to do with the ... -- a chemical known to promote sleepiness, said Donna ...
    ... on the future treatment of breast cancer have been identified ... published in the online open access journal Breast Cancer Research ... priorities. , A team led by Professor Mitch Dowsett, ... based in London and Surrey, together with colleagues from the ...
    ... Health Company,(Amex: FHC ) today announced that it ... Analyst Conference on Wednesday, November 28,2007 at the Princeton ... 5th and,6th). The Company,s CEO, O.B. Parrish, and its ... a.m. Eastern Time (EST)., A "live" webcast of ...
    ... more ozone, and more strain on hearts, researchers say ... and high ozone levels work together to boost death ... They believe that global warming -- which brings more ... number of people who die of cardiovascular events. , ...
    Cached Medicine News:
    ... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
    ... II Hybrid External Fixation System incorporating ... in hybrid fixation. It incorporates features ... is designed to offer speed of ... Hoffmann® snap-fit technology. , ,Using the ...
    ... to add individual components for individual indications. ... indications. Made of an innovative composite plastic ... only much lighter. This means it's easier ... comfortable for the patient. ,Come pre-assembled, packaged ...
    The Hybrid Fixator consists of Three basic components: rings, wires, clamps. Final fracture reduction can be easily performed after frame assembly....
    Medicine Products: